PerfuseCell Cronus A/S: Financial statements 2024
CVR: 31606810
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
PerfuseCell Cronus A/S (CVR 31606810) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 625,171 and a net result of DKK 2,216 compared with DKK 171,478 the year before. That is a decrease of 12.1% compared with the year before. The profit margin was 0.4%. Equity in the 2024 report amounted to DKK 1,046,863. The solvency ratio was 69.1%.
- Revenue
- DKK 625,171
- Gross Profit
- DKK -15
- Profit/Loss
- DKK 2,216
- Equity
- DKK 1,046,863
- Total Assets
- DKK 1,515,613
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 625 t. | -15 | 2 t. | 1 mio. | - |
| 2023 | 711 t. | 150 t. | 171 t. | 1 mio. | - |
| 2022 | 550 t. | 131 t. | 89 t. | 873 t. | - |
| 2021 | 150 t. | 34 t. | 34 t. | 784 t. | - |
| 2020 | 385 t. | 87 t. | 87 t. | 750 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of November 13, 2024, Flemming Petersen is registered as director of PerfuseCell Cronus A/S.
As of November 13, 2024, Per Stobbe has stepped down as adm. dir. of PerfuseCell Cronus A/S.
PerfuseCell Cronus A/S has published its annual report for 2023. Revenue came to DKK 711,014, and the net result was DKK 171,478.
About PerfuseCell Cronus A/S
PerfuseCell Cronus A/S is a Danish company of the type Aktieselskab based in Herlev, founded in 2008. The company is registered under the industry Fremstilling af medicinske og dentale instrumenter samt udstyr hertil. The company was previously named PerfuseCell A/S and PumpCell A/S. The management consists of Per Stobbe. The board consists of August Kisling Stobbe, Flemming Petersen and Per Stobbe. The company is owned by Stobbe GmbH. In 2025, the company reported a gross profit of DKK 20,467 and a net result of DKK 23,973 compared with DKK 2,216 the year before. Equity in the 2025 report amounted to DKK 1,070,836.